Literature DB >> 9538962

The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes.

K V Williams1, M L Mullen, D E Kelley, R R Wing.   

Abstract

OBJECTIVE: To determine whether an intermittent very-low-calorie diet (VLCD) improves weight loss and glycemic control more than moderate caloric restriction alone. RESEARCH DESIGN AND METHODS: Individuals with type 2 diabetes (n = 54) who were > or = 20% over ideal body weight participated in a 20-week behavioral weight control program. Subjects were randomized to either a standard behavioral therapy (SBT) group or to one of two VLCD groups. SBT subjects received a 1,500-1,800 kcal/day diet throughout. Both VLCD groups followed a VLCD for 5 consecutive days during week 2, followed by either intermittent VLCD therapy for 1 day/week for 15 weeks (1-day) or for 5 consecutive days every 5 weeks (5-day), with a 1,500-1,800 kcal/day diet at other times.
RESULTS: Both VLCD groups lost more weight than the SBT group over the 20 weeks (P = 0.04). Although the groups did not differ in fasting plasma glucose (FPG) changes at 20 weeks, more subjects in the 5-day group attained a normal HbA1c when compared with the SBT group (P = 0.04). This benefit was independent of the effects of weight loss. The best predictor of overall change in FPG and HbA1c was the FPG response during the first 3 weeks of the program.
CONCLUSIONS: Periodic VLCDs improved weight loss in diabetic subjects. A regimen with intermittent 5-day VLCD therapy seemed particularly promising, because more subjects in this group attained a normal HbA1c. Moreover, the glucose response to a 3-week period of diet therapy predicted glycemic response at 20 weeks, and it was a better predictor of the 20-week response than initial or overall weight loss.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9538962     DOI: 10.2337/diacare.21.1.2

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  50 in total

Review 1.  Nutrition therapy for overweight children and adolescents with type 2 diabetes.

Authors:  Emily S Loghmani
Journal:  Curr Diab Rep       Date:  2005-10       Impact factor: 4.810

Review 2.  Impact of intermittent fasting on health and disease processes.

Authors:  Mark P Mattson; Valter D Longo; Michelle Harvie
Journal:  Ageing Res Rev       Date:  2016-10-31       Impact factor: 10.895

3.  Very-low-energy diet for type 2 diabetes: an underutilized therapy?

Authors:  Amy E Rothberg; Laura N McEwen; Andrew T Kraftson; Christine E Fowler; William H Herman
Journal:  J Diabetes Complications       Date:  2014-03-29       Impact factor: 2.852

Review 4.  NRF2, cancer and calorie restriction.

Authors:  A Martín-Montalvo; J M Villalba; P Navas; R de Cabo
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

5.  Calorie Restriction and Intermittent Fasting: Impact on Glycemic Control in People With Diabetes.

Authors:  Kavitha Ganesan; Yacob Habboush; Samuel Dagogo-Jack
Journal:  Diabetes Spectr       Date:  2020-05

6.  Intermittent Fasting and Human Metabolic Health.

Authors:  Ruth E Patterson; Gail A Laughlin; Andrea Z LaCroix; Sheri J Hartman; Loki Natarajan; Carolyn M Senger; María Elena Martínez; Adriana Villaseñor; Dorothy D Sears; Catherine R Marinac; Linda C Gallo
Journal:  J Acad Nutr Diet       Date:  2015-04-06       Impact factor: 4.910

Review 7.  Obesity and sedentary lifestyle: modifiable risk factors for prevention of type 2 diabetes.

Authors:  E J Mayer-Davis; T Costacou
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

8.  Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes.

Authors:  Elizabeth F Sutton; Robbie Beyl; Kate S Early; William T Cefalu; Eric Ravussin; Courtney M Peterson
Journal:  Cell Metab       Date:  2018-05-10       Impact factor: 27.287

9.  A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes.

Authors:  Yunsheng Ma; Barbara C Olendzki; Philip A Merriam; David E Chiriboga; Annie L Culver; Wenjun Li; James R Hébert; Ira S Ockene; Jennifer A Griffith; Sherry L Pagoto
Journal:  Nutrition       Date:  2008-01       Impact factor: 4.008

10.  Metreleptin improves blood glucose in patients with insulin receptor mutations.

Authors:  Rebecca J Brown; Elaine Cochran; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2013-08-22       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.